Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oman Healthcare News.
Press releases published on July 4, 2025
Spectral Medical Inc. Announces Filing of Base Shelf Prospectus
TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has filed a preliminary short …
The Dermatology Group of Arkansas Welcomes Double Board-Certified Dermatologist to Practice
LITTLE ROCK, Ark., July 04, 2025 (GLOBE NEWSWIRE) -- The Dermatology Group of Arkansas are thrilled to welcome their newest, double board-certified specialist, Dr. Jessica Pillow, who joins the Little Rock, skin care-focused practice this summer. Dr. …
Seule la transparence et la responsabilité peuvent sauver le CERN : une condition essentielle pour mettre fin au gaspillage de milliards et accélérer les innovations médicales vitales
DALLAS, 04 juill. 2025 (GLOBE NEWSWIRE) -- La Crosetto Foundation for the Reduction of Cancer Deaths, une organisation à but non lucratif agréée, lance un « appel urgent aux membres du Parlement européen et des parlements nationaux : il faut geler les …
Nur Transparenz und Rechenschaftspflicht können das CERN retten: Milliardenverschwendung stoppen, lebensrettende Innovationen ermöglichen
DALLAS, July 04, 2025 (GLOBE NEWSWIRE) -- Die Crosetto Foundation for the Reduction of Cancer Deaths, eine anerkannte gemeinnützige Organisation, richtet einen „dringenden Appell an die Mitglieder des Europäischen Parlaments und der nationalen Parlamente: …
Chiropractor Posture Correction: Colm Murph of Brighton Chiropractic Office Shares Advice in HelloNation
Brighton, N.Y., July 04, 2025 (GLOBE NEWSWIRE) -- What are the daily habits that help prevent back pain before it starts? According to Colm Murph, chiropractor and owner of Brighton Chiropractic Office, understanding how posture influences spinal health is …
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr. Lawrence Steinman have joined Immuthera’s Scientific Advisory …
L’eau, la boisson vedette de plus de 42 000 jeunes avec le Défi Tchin-tchin dans mon camp!
MONTRÉAL, 04 juill. 2025 (GLOBE NEWSWIRE) -- Cette semaine, du 30 juin au 4 juillet, plus de 42 000 jeunes campeur·euse·s à travers le Québec ont levé leur verre d’eau bien haut pour célébrer l’importance d’une saine hydratation! En relevant le Défi Tchin- …
Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets™
Delray Beach, FL, July 04, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Sodium Perborate Market is expected to reach USD 184.0 million in 2030 from USD 153.3 million in 2025, registering a CAGR of 3.7%, as per the recent study by MarketsandMarkets™. …
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with …
AB Science : Le masitinib reçoit l'autorisation de la FDA et de l'EMA pour l’etude confirmatoire de phase 3 dans le cancer de la prostate métastatique hormono-resistant
COMMUNIQUÉ DE PRESSE LE MASITINIB REÇOIT L'AUTORISATION DE LA FDA ET DE L'EMA POUR L’ETUDE CONFIRMATOIRE DE PHASE 3 DANS LE CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RESISTANT, AVEC UNE SÉLECTION DES PATIENTS BASÉE SUR DES BIOMARQUEURS CIBLANT LA …
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO BENEFIT Paris, July 4, 2025, 8am CET AB …
Strüngmann Award zeichnet Gründerteam von Araris Biotech als Preisträger 2025 aus
Die Expertenjury wählte Dr. Dragan Grabulovski, Dr. Philipp Spycher und Dr. Isabella Attinger-Toller von Araris Biotech, aus einer Gruppe herausragender Life-Science-Unternehmer aus Das Gründerteam von Araris Biotech entwickelt eine bahnbrechende …
Strüngmann Award Honors Araris Biotech Founding Team as 2025 Winner
The expert jury selected Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D. of Araris Biotech, from a group of outstanding life science entrepreneurs The founding team is developing a breakthrough technology to establish …